Vistagen Therapeutics Plans To Launch The Palisade-3 Trial In 1H Of 2024 And Palisade-4 In 2H Of 2024 - 8K
Portfolio Pulse from Benzinga Newsdesk
Vistagen Therapeutics plans to launch the Palisade-3 trial in the first half of 2024 and Palisade-4 in the second half of 2024. If successful, these trials, along with Palisade-2, may provide substantial evidence of the effectiveness of fasedienol, potentially leading to a U.S. New Drug Application for the acute treatment of anxiety in adults with SAD in the first half of 2026.
October 02, 2023 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vistagen Therapeutics' upcoming trials could potentially lead to a New Drug Application for fasedienol, which could have a significant impact on the company's future revenues and stock price.
The success of the upcoming trials could lead to a New Drug Application for fasedienol, a drug for the acute treatment of anxiety in adults with SAD. This could potentially increase the company's revenues and positively impact the stock price. However, the trials are still in the future and their success is not guaranteed.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100